Department of Medicine III-Oncology, University of Medicine and Pharmacy Grigore T Popa, Iasi, Romania.
Department of Medicine II-Nursing/Palliative Care, University of Medicine and Pharmacy Grigore T Popa, Iasi, Romania.
Expert Rev Anticancer Ther. 2021 Mar;21(3):315-323. doi: 10.1080/14737140.2021.1852933. Epub 2020 Dec 3.
: In the elderly non-small cell lung cancer (NSCLC) is more commonly diagnosed in advanced stages. Conservative therapy including chemotherapy in this age group might be challenging because one of the criteria for its indication is the appropriate functional status, and in the elderly this is more difficult to ascertain. Checkpoint inhibitors are recent therapies found to be effective alone or in combinations in patients with advanced NSCLC, but little is known about their efficacy and their safety in such patients.: We review clinical studies of checkpoint inhibitors in patients with advanced NSCLC in an attempt to identify peculiarities related to their use in the elderly. The clinical studies discussed enrolled a significant proportion of elderly patients and for some compounds, post-hoc analysis in the elderly was performed. Efficacy data supports the use of such compounds in the elderly and the safety profile is acceptable for all molecules discussed.: In the elderly with advanced NSCLC, checkpoint inhibitors are efficacious and well tolerated and may be appropriate for use in patients with an increased impaired functional status. Furthermore, in this category of patients this therapy may be used as a neoadjuvant therapy in order to improve the resectability of the tumor.
在老年非小细胞肺癌（NSCLC）中，更常见的是在晚期诊断。在这个年龄段，包括化疗在内的保守治疗可能具有挑战性，因为其适应证的标准之一是适当的功能状态，而在老年人中，这更难以确定。检查点抑制剂是最近发现的单独或联合用于晚期 NSCLC 患者的有效疗法，但对于这些患者的疗效和安全性知之甚少。我们回顾了检查点抑制剂在晚期 NSCLC 患者中的临床研究，试图确定与老年患者使用这些药物相关的特点。所讨论的临床研究纳入了相当比例的老年患者，并且对于一些化合物，在老年患者中进行了事后分析。疗效数据支持在老年患者中使用这些化合物，并且所有讨论的分子的安全性特征是可以接受的。在晚期 NSCLC 的老年患者中，检查点抑制剂有效且耐受良好，对于功能状态受损增加的患者，可能适合使用。此外，在这一类患者中，这种治疗方法可作为新辅助治疗，以提高肿瘤的可切除性。
